Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – Should You Sell?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s share price gapped down before the market opened on Monday . The stock had previously closed at $21.87, but opened at $21.10. Chugai Pharmaceutical shares last traded at $20.9540, with a volume of 8,498 shares.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Zacks Research raised Chugai Pharmaceutical to a “hold” rating in a research report on Friday, May 29th. The Goldman Sachs Group raised Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, June 15th. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy”.

Chugai Pharmaceutical Price Performance

The firm has a fifty day simple moving average of $23.40 and a two-hundred day simple moving average of $26.39. The firm has a market capitalization of $68.96 billion, a P/E ratio of 22.77 and a beta of 0.59.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its quarterly earnings data on Friday, July 24th. The company reported $0.22 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a return on equity of 23.71% and a net margin of 35.09%.The business had revenue of $2.14 billion for the quarter, compared to analysts’ expectations of $2.38 billion. On average, research analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.98 EPS for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.